Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1
Clinical Trials Related to Cyclophosphamide
Related studies linked through entity extraction aliases.
Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis
- Status
- COMPLETED
- Phase
- PHASE2
Hematopoietic Stem Cell Transplant for Fanconi Anemia
- Status
- COMPLETED
- Phase
- PHASE2
Safety Study of DNA Vaccine Delivered by Intradermal Electroporation to Treat Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment
- Status
- COMPLETED
- Phase
- N/A
Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma
- Status
- COMPLETED
- Phase
- PHASE2
S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma
- Status
- WITHDRAWN
- Phase
- PHASE2
Anthracycline-free Taxane Based Chemotherapy in Patients With HER2/Neu Negative Early Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features
- Status
- COMPLETED
- Phase
- PHASE1
Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis
- Status
- WITHDRAWN
- Phase
- PHASE2
Trial of Activated Marrow Infiltrating Lymphocytes Alone or in Conjunction With an Allogeneic Granulocyte Macrophage Colony-stimulating Factor (GM-CSF)-Based Myeloma Cellular Vaccine in the Autologous Transplant Setting in Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders
- Status
- COMPLETED
- Phase
- PHASE2
Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Biochemical Correction of Severe EB by Allo HSCT and "Off-the-shelf" MSCs
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Cyclophosphamide, Methotrexate, and Fluorouracil, With or Without Epirubicin Hydrochloride, in Treating Women Who Have Undergone Surgery for Breast Cancer (Group III Closed to New Patients as of 12/7/2009)
- Status
- UNKNOWN
- Phase
- PHASE3
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
- Status
- TERMINATED
- Phase
- PHASE2